Patient Access Solutions, Inc.

Patient Access Solutions, Inc. provides healthcare/financial processing solutions for the healthcare and dental industries. The company, through its merchant processing platform, provides patient eligibility, medical billing, and patient self-pay solutions. It also provides practice management, business management consulting, GAP analysis, and marketing and practice development services; and treatment services for autism, concussion, PTSD, and other biomedical conditions, as well as diagnostic testing services. Patient Access Solutions, Inc. is based in Plainview, New York.

Patient Access Solutions, Inc. trades as PASO on OTC. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $212,736 of revenue and -$10.59M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Patient Access Solutions, Inc. can be compared against peers such as Arrayit Corporation, AVAX Technologies, Inc., Braxia Scientific Corp., Item 9 Labs Corp., Interpharm Holdings, Inc., Jack Nathan Medical Corp..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $74,059, beta of 0.21, and return on equity of +541.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PASO currently shows total debt of $925,373 and beta of 0.21. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.pashealth.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.